Novartis's Entresto Doesn't Impress In 1Q; Orphan Drug Fails In PhIII
This article was originally published in Scrip
Novartis AG's newly launched heart failure drug Entresto (valsartan/sacubitril), which has been dubbed the company's next blockbuster product, missed the mark in the first quarter of the year, posting sales more than $10m below analyst forecasts.
You may also be interested in...
Sales prospects for Novartis AG's struggling Entresto have been boosted – especially in the US – by new global cardiology guidelines issued by three organizations containing stronger than expected recommendations for its use in treating heart failure.
Ten years at AstraZeneca PLC have prepared US President and Executive Vice President of North America Paul Hudson for his next C-suite job, but unfortunately for his current employer that gig is with a major competitor – Novartis AG.
The innovative nature of Novartis's new chronic heart failure therapy Entresto counted towards NICE's appraisal committee clearing its use in Britain's National Health Service, despite a cost-effectiveness ratio that was close to the upper limit for gaining a positive recommendation.